Biotech Values

[DewDiligence]

The Teva-Lonza FoB collaboration announced in 2009 (#msg-34930012) appears to be dead, for all practical purposes:

http://www.reuters.com/article/2013/03/30/lonza-teva-biosimilars-idUSL5N0CM04H20130330

Swiss specialty chemicals and life sciences group Lonza is reviewing whether it is still worth investing in its joint venture with Teva in "biosimilar" drugs, its Chief Executive said.

You don’t tell Reuters something like this unless the collaboration really is kaput.

As a MNTA shareholder, I’m happy to see companies other than MNTA and BAX pulling out of the FoB arena.